#Prader-Willi Press Releases

Levo Therapeutics Announces Initiation of the CARE-PWS Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome

Levo Therapeutics, Inc. announced today that enrollment is underway in its Phase 3 clinical study of intranasal carbetocin (LV-101) for the treatment of Prader-Willi syndrome (PWS). The study is a multi-center, randomized, double-blind, placebo-controlled study called CARE-PWS.  “We are excited to bring…


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login